Kepos Capital’s Esperion Therapeutics ESPR Stock Holding History

Kepos Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-22,538	Closed	-$1.05M	–	339
2019 Q2	$1.05M	Buy	+22,538	New	+$1.06M	0.11%	164

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Kepos Capital's ESPR Position: Q3 2019 in Review

Kepos Capital sold out of Esperion Therapeutics (ESPR) in Q3 2019, closing a stake of 22,538 shares — an estimated $1.05M sold.

Kepos Capital first reported a position in ESPR in Q2 2019 and held it in 1 quarter. The position peaked at $1.05M in Q2 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Kepos Capital reported no remaining Esperion Therapeutics position as of Q3 2019 after selling out during the quarter.
Kepos Capital sold 22,538 Esperion Therapeutics shares in Q3 2019, an estimated $1.05M.
Kepos Capital first reported a position in Esperion Therapeutics in Q2 2019 and held it in 1 quarter.
Kepos Capital's Esperion Therapeutics position peaked at $1.05M in Q2 2019.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Kepos Capital's 13F filing for Q3 2019, filed 13 Nov 2019.